AHA Scientific Sessions 2020 – Live Rebroadcast and Q&A – CCM® for Heart Failure: The Class Effect

The importance of accurately assessing the NYHA classification of patients with Heart Failure has never been higher! For almost two decades, the only device available to treat Heart Failure have been cardiac resynchronization (CRT) devices. But now everything has changed. The FDA has approved a breakthrough device for the treatment of Heart failure, and the ability to utilize it depends heavily on accurate NYHA assessment. This treatment can address the almost 1.2M patients who are not candidates for CRT in the US, but only if cardiologists can identify and refer them appropriately. This lecture will explain what Cardiac Contractility Modulation therapy is, how it works, and what you can expect in terms of outcomes when utilizing this treatment for NYHA Class III patients who remain symptomatic in spite of guideline directed medical therapy. The faculty will share their personal experiences and what they have learned about CCM® therapy using case-based examples that include the means by which they have increased their awareness of how to identify appropriate candidates for this important new device therapy for patients with heart failure who have few or no other options.

PRESENTERS